| Species |
Rat |
| Protein Construction |
FGF-9 (Leu4-Ser208)
Accession # P36364 |
|
| Purity |
> 95% as analyzed by SDS-PAGE
> 95% as analyzed by HPLC |
| Endotoxin Level |
< 1 EU/μg of protein by LAL method |
| Biological Activity |
Fully biologically active when compared to standard. The ED50 as determined by thymidine uptake assay using FGF-receptors transfected BaF3 cells is less than 0.5 ng/ml, corresponding to a specific activity of > 2.0 × 106 IU/mg. |
| Expression System |
E. coli |
| Theoretical Molecular Weight |
23.1 kDa |
| Formulation |
Lyophilized from a 0.2 μm filtered solution in 20 mM Tris, 400 mM NaCl, pH 8.0. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Fibroblast growth factor 9 (FGF-9) belongs to the large FGF family which has at least 23 members. All FGF family members are heparin binding growth factors with a core 120 amino acid (a.a.) FGF domain that allows for a common tertiary structure. FGF-9 targets glial cells, astrocytes cells and other cells that express the FGFR 1c, 2c, 3b, 3c, and 4. |
| Synonyms |
Fibroblast Growth Factor-9; FGF9; GAF; Glia-activating factor; HBGF-9 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
